CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Bought by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 14.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,423 shares of the company’s stock after buying an additional 829 shares during the period. Atria Wealth Solutions Inc.’s holdings in CRISPR Therapeutics were worth $402,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. ARK Investment Management LLC grew its position in CRISPR Therapeutics by 19.2% during the fourth quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock valued at $534,360,000 after acquiring an additional 1,372,986 shares during the period. Vanguard Group Inc. grew its holdings in shares of CRISPR Therapeutics by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,538,725 shares of the company’s stock worth $69,843,000 after purchasing an additional 7,635 shares during the period. Armistice Capital LLC raised its holdings in CRISPR Therapeutics by 20.0% in the third quarter. Armistice Capital LLC now owns 600,012 shares of the company’s stock valued at $27,235,000 after buying an additional 100,012 shares during the period. Barclays PLC lifted its position in CRISPR Therapeutics by 36.9% during the third quarter. Barclays PLC now owns 510,832 shares of the company’s stock valued at $23,186,000 after buying an additional 137,629 shares in the last quarter. Finally, Baillie Gifford & Co. grew its stake in CRISPR Therapeutics by 81.1% during the third quarter. Baillie Gifford & Co. now owns 441,063 shares of the company’s stock worth $20,020,000 after buying an additional 197,469 shares during the period. 69.20% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at CRISPR Therapeutics

In related news, General Counsel James R. Kasinger sold 1,913 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the completion of the transaction, the general counsel now owns 57,371 shares of the company’s stock, valued at $4,570,747.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CEO Samarth Kulkarni sold 19,582 shares of CRISPR Therapeutics stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the transaction, the chief executive officer now owns 208,122 shares of the company’s stock, valued at approximately $12,468,589.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel James R. Kasinger sold 1,913 shares of the company’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $152,408.71. Following the sale, the general counsel now directly owns 57,371 shares of the company’s stock, valued at $4,570,747.57. The disclosure for this sale can be found here. Insiders have sold 83,992 shares of company stock worth $6,132,335 over the last quarter. 4.10% of the stock is currently owned by company insiders.

CRISPR Therapeutics Trading Up 2.1 %

Shares of CRISPR Therapeutics stock opened at $57.06 on Tuesday. The business’s 50 day simple moving average is $67.17 and its 200-day simple moving average is $64.60. The stock has a market capitalization of $4.84 billion, a price-to-earnings ratio of -29.11 and a beta of 1.80. CRISPR Therapeutics AG has a twelve month low of $37.55 and a twelve month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.95. The business had revenue of $201.20 million during the quarter, compared to the consensus estimate of $148.72 million. The company’s revenue for the quarter was up 3253.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.41) EPS. Sell-side analysts predict that CRISPR Therapeutics AG will post -6.24 earnings per share for the current year.

Analyst Ratings Changes

CRSP has been the topic of a number of research reports. Wolfe Research started coverage on shares of CRISPR Therapeutics in a report on Thursday, February 15th. They set a “peer perform” rating on the stock. Wells Fargo & Company increased their target price on CRISPR Therapeutics from $55.00 to $70.00 and gave the company an “equal weight” rating in a research note on Thursday, February 22nd. Needham & Company LLC reissued a “buy” rating and set a $90.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, April 11th. TheStreet raised shares of CRISPR Therapeutics from a “d+” rating to a “c” rating in a research report on Friday, February 23rd. Finally, Chardan Capital boosted their target price on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $76.29.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.